title: [The cardiovascular safety of cyclooxygenase-2 (COX-2) inhibitors].
authors.forename: D
authors.initials: D
authors.lastname: Hasdai
authors.forename: S
authors.initials: S
authors.lastname: Gottlieb
authors.forename: U
authors.initials: U
authors.lastname: Godbourt
authors.forename: H
authors.initials: H
authors.lastname: Hod
authors.forename: E
authors.initials: E
authors.lastname: Kaluski
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D012449:Safety
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases